Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Thrombin time" patented technology

The thrombin time (TT), also known as the thrombin clotting time (TCT) is a blood test that measures the time it takes for a clot to form in the plasma of a blood sample containing anticoagulant, after an excess of thrombin has been added. It is used to diagnose blood coagulation disorders and to assess the effectiveness of fibrinolytic therapy. This test is repeated with pooled plasma from normal patients. The difference in time between the test and the 'normal' indicates an abnormality in the conversion of fibrinogen (a soluble protein) to fibrin, an insoluble protein.

Prediction model for differential diagnosis of lumbar major muscle abscess type and application thereof

PendingCN121862432AMedical data miningEnsemble learningSerum uric acidAbsolute neutrophil count
The invention belongs to the technical field of medical diagnosis, and particularly relates to a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscesses and interactive application. According to the invention, it is found that six indexes including serum uric acid (UA), thrombin time (TT), neutrophil absolute value (NEUT #), age (Age), fever (Fever) and erythrocyte sedimentation rate (ESR) are related to the type of the lumbar major muscle abscess, and a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscess and interactive application are invented. And a first visual and quantifiable column diagram (Nomogram) prediction model for differential diagnosis of lumbar major muscle abscess is provided for the field. The technical problem that an abstract mathematical prediction model is converted into a visual graphic diagnosis tool which is intuitive in form and convenient to operate is solved, so that the visual graphic diagnosis tool can be separated from dependence on specific computing equipment, and clinical medical staff can quickly and accurately apply the visual graphic diagnosis tool on a diagnosis and treatment site conveniently.
Owner:BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1

Antibacterial and anticoagulant coating material for blood contact material and application of antibacterial and anticoagulant coating material

The invention belongs to biomedical materials, and particularly relates to an antibacterial and anticoagulant coating material for a blood contact material and application of the antibacterial and anticoagulant coating material. The antibacterial and anticoagulant coating material comprises copper tetracarboxyl phenyl porphyrin loaded with an anticoagulant and water-soluble polysaccharide. A coating formed on the basis of the antibacterial and anticoagulant coating material can achieve antibacterial and anticoagulant effects at the same time, for example, the bacteriostasis rate on escherichia coli and the bacteriostasis rate on staphylococcus epidermidis can reach 90%; in addition, the activated part thromboplastin time, prothrombin time and thrombin time of the coating are obviously higher than those of an untreated blood contact material; and the hemolysis rate is lower than 5%.
Owner:CHONGQING TIANWAITIAN BIOTECHNOLOGY CO LTD

Thrombin solution, kit, method for stabilizing thrombin, detection reagent, method for determining thrombin time, and use of an antifoam

A thrombin solution, a kit, a method for stabilizing thrombin, a detection reagent, and a method for measuring thrombin time. The thrombin solution contains thrombin and contains an antifoaming agent. The thrombin solution has improved stability, enabling the thrombin to remain stable for a long time even at a low activity.
Owner:SEKISUI MEDICAL TECH SUZHOU LTD +1

Method for establishing blood coagulation disorder animal model

The invention belongs to the field of basic medicine, and particularly relates to a method for establishing a blood coagulation disorder animal model, which comprises the following steps of: performing intragastric administration on a healthy rat with a preparation containing podophyllotoxin according to the dose of 10mg / kg per day, and continuously performing administration for 4 days; wherein the drug administration can induce the rat to generate blood coagulation disorder phenotypes, and the phenotypes at least comprise prothrombin time prolonging, activated partial thromboplastin time prolonging and thrombin time prolonging. According to the establishment method of the blood coagulation disorder animal model, it is determined that podophyllotoxin can cause whole-body blood coagulation disorder, and the stable and repeatable blood coagulation disorder animal model is provided.
Owner:THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF SCI & TECH

Allicium verum polysaccharide, extraction and separation method thereof and application of illicium verum polysaccharide in preparation of anticoagulant drugs

The invention discloses an extraction and separation method of anise polysaccharide with anticoagulant activity. The method comprises the following steps: crushing fresh anise, extracting with hot water, concentrating a water extract, and adding ethanol for precipitation to obtain crude polysaccharide; removing protein by adopting a Sevage method; and dialyzing to remove small molecular impurities, and freeze-drying to obtain the purified anise polysaccharide. The molecular weight of the polysaccharide is about 72.053 kDa. In-vitro coagulation experiments show that the polysaccharide can significantly prolong prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) and reduce the content of fibroblast egg (FIB) white, and shows significant anticoagulant activity. The star anise polysaccharide provided by the invention can be used for preparing anticoagulant drugs, and has the advantages of wide raw material source, simple extraction process, definite activity and the like.
Owner:HENAN UNIVERSITY

A method and system for classifying blood samples in coagulation index detection based on MAML and spatial transformation

The present application relates to the field of machine learning, in particular to a blood sample classification method and system for coagulation index detection based on MAML and spatial transformation, mainly using a spatial transformation module to classify coagulation indexes, the specific steps comprising: obtaining the curve images of prothrombin time (PT) and thrombin time (TT) samples, extracting features and creating a training set and a test set; inputting the training set images into a module combining spatial transformation and convolution network to generate processed images; then updating parameters using gradient descent of the training model, reconstructing a spatial transformation coagulation index classification model; setting hyperparameters for the abnormal coagulation index classification model; finding the optimal model training process through model training and iterative testing to realize the classification of coagulation indexes. The present application uses MAML algorithm and spatial transformation to gradually optimize a small number of samples to achieve good generalization ability, and combines neural network structure and learning algorithm, which has wide applicability and flexibility.
Owner:SHANDONG NORMAL UNIV

Use of sodium thiocyanate in the preparation of a kit for the detection of coagulation items

This invention discloses the application of sodium thiocyanate in the preparation of a kit for coagulation assays. The kit detects coagulation parameters based on coagulation methods, chromogenic substrate methods, or immunoturbidimetric assays. These coagulation parameters include prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, fibrin(ogen) degradation products, D-dimer, antithrombin III, and anti-Xa. By adding sodium thiocyanate to the coagulation assay kit, this invention optimizes the clinical relevance of the assay kit by adjusting reaction time (coagulation method), improving the linear range (chromogenic substrate method), and enhancing the differentiation between low and high values ​​(immunoturbidimetric assay), thereby improving the accuracy of the test.
Owner:WUHAN EASYDIAGNOSIS BIOMEDICINE

Prediction model for early warning of leukemia sepsis

The invention discloses a prediction model for early warning of leukemia sepsis, and belongs to the technical field of medical information. Immunosuppression and infection of leukemia patients are rapidly deteriorated, and existing indexes and models are low in sensitivity and difficult to recognize sepsis in time. According to the system, eight conventional indexes, namely C reactive protein, procalcitonin, neutrophil counting, lymphocyte counting, thrombin time, red blood cell counting, total bile acid and systolic pressure, of the first day of admission are extracted, key features are screened through single-factor logistic regression, LASSO and Boruta algorithms in a combined mode, a random forest model is trained, and 10-fold cross validation and grid search optimization are conducted; a nonlinear relation is analyzed by combining SHAP explanation and a restrictive cubic spline, AUC0.765 is trained, AUC0.700 is verified, individualized risk scoring is provided, a hospital information system is embedded, clinical early intervention is guided, and death is reduced.
Owner:AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIV +1

Factor XI catalytic domain-binding antibodies and methods of use thereof

The present disclosure provides antibodies that bind to the catalytic domain of factor XI (FXI) and methods of use thereof. According to certain embodiments, the antibodies are antagonistic antibodies that inhibit clot formation via the intrinsic pathway without affecting hemostasis, as demonstrated by their ability to prolong aPTT without affecting PT. Thus, these antagonistic antibodies can be used in the treatment or therapeutic regimen of blood clotting diseases or disorders that have clot formation as a risk factor, such as, but not limited to, atrial fibrillation. In certain embodiments, the present disclosure includes antibodies that bind to FXI and mediate clot or thrombus formation. The antibodies of the present disclosure can be fully human, non-naturally occurring antibodies.
Owner:REGENERON PHARMACEUTICALS INC

Clinical diagnosis model for early diagnosis of SFTS concurrent AP and construction method thereof

The invention relates to a clinical diagnosis model for early diagnosis of fever with thrombocytopenia syndrome (SFTS) complicated by acute pancreatitis (AP) and a construction method thereof. The model is constructed through Logistic regression analysis and LASSO regression analysis on the basis of indexes such as virus load (DBV RNA), thrombin time (TT), amylase (AMY) and blood calcium (Ca). The model shows good distinction degree and calibration degree in a training queue and a verification queue, can effectively predict the risk of concurrent AP of the SFTS patient, and has relatively high clinical practicability and prediction accuracy.
Owner:JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY) +2